Skip to main content
. 2019 Dec 5;111(1):229–238. doi: 10.1111/cas.14238

Figure 4.

Figure 4

Comparison of bone marrow transplantation (BMT) therapy for 5‐year event‐free survival (EFS) and overall survival (OS) in relapsed acute lymphoblastic leukemia (ALL) patients with TP53 alterations. A, 5‐year EFS for relapsed ALL patients with TP53 wild‐type (WT) and TP53 alterations. B, 5‐year OS for relapsed ALL patients with TP53 WT and TP53 alterations